Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

Lignende værker

• Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
  af: Ebata, Takahiro, et al.
  Udgivet: (2019)
• First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
  af: Kondo, Shunsuke, et al.
  Udgivet: (2021)
• First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
  af: Koyama, Takafumi, et al.
  Udgivet: (2020)
• Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
  af: Shimomura, Akihiko, et al.
  Udgivet: (2017)
• Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
  af: Fujiwara, Yutaka, et al.
  Udgivet: (2020)